Le Lézard
Classified in: Health, Science and technology

Junshi Biosciences Announces Approval of "B" Marker Removal from Company's Stock Name by HKEX

SHANGHAI, China, July 12, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that following its application to The Stock Exchange of Hong Kong Limited (HKEX) pursuant to Rule 18A.12 of the Rules Governing the Listing of Securities on HKEX (Listing Rules), HKEX has granted approval for the dis-application of Rules 18A.09 to 18A.11 of the Listing Rules. Junshi Biosciences originally listed on the HKEX on December 24, 2018 under Chapter 18 A (the biotech chapter) of the Listing Rules. It now satisfies and even well surpasses the revenue and market capitalization requirements for the dis-application.

As a result of the approval by the HKEX, the "B" marker will no longer be affixed to the Company's stock name in the HKEX.

About Junshi Biosciences

Established in 2012, Junshi Biosciences is committed to developing first-in-class and best-in-class drugs through original innovation and becoming a pioneer in the area of translational medicine to provide patients with effective and affordable treatment options. On December 24, 2018, Junshi Biosciences was listed on the Main Board of the Stock Exchange of Hong Kong with the stock code: 1877.HK. The Company has established a diversified R&D pipeline comprising 21 drug candidates with therapeutic areas covering cancer, metabolic diseases, autoimmune diseases, and neurologic diseases. Product types include monoclonal antibodies, fusion proteins, antibody drug conjugates, and small molecule drugs. With a combined 33,000L fermentation capacity in two GMP facilities at Shanghai and Wujiang, Junshi has established the manufacturing infrastructure to support commercialization and provide our partners and patients with high-quality products through a global supply chain network. For more information, please visit: http://junshipharma.com/en/Index.html

Contact Information

IR Team:
+ 86 021-2250 0300

Solebury Trout
Bob Ai
+1 646-389-6658

These press releases may also interest you

at 03:04
- Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of Non-Hodgkin's Lymphoma (NHL), representing 30-40% of cases. Nearly half of DLBCL patients are not cured by first-line treatment, leaving a large number of patients at risk...

at 03:00
Chinese biotechnology company Vazyme will showcase a rich lineup of products at the 2021 Medlab Middle East, a leading medical laboratory exhibition co-located with Arab Health. The live in-person event is scheduled to take place from 21 to 24 June,...

at 02:45
The Health Economics Outcomes Research (HEOR) Services, prices will increase by 3%-8% during the forecast period and suppliers will have moderate bargaining power in this market. Request a Free Sample Report to Know More The report provides a...

at 02:29
A KAIST research team has developed a bioinspired flexible piezoelectric acoustic sensor with multi-resonant ultrathin piezoelectric membrane mimicking the basilar membrane of the human cochlea. The flexible acoustic sensor has been miniaturized for...

at 02:05
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, today announces that it has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer. The trial will evaluate the...

at 02:02
Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, has released two video presentations related to the ONCOS-102 mesothelioma 24-month data. The 24-month follow-up...

News published on 12 july 2020 at 08:25 and distributed by: